Chan John K, Berek Jonathan S
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford Cancer Center, Stanford, CA 94305, USA.
J Clin Oncol. 2007 Jul 10;25(20):2975-82. doi: 10.1200/JCO.2007.10.8662.
During the last decade, research progress on cervical cancer has elucidated the role of human papilloma virus (HPV) in the pathogenesis of cervical cancer. Clinical trials on the viral-like particle HPV vaccines have good safety profiles and promising efficacy in preventing genital warts, cervical neoplasia, and cervical cancer. The implementation of the HPV vaccine is a tremendous milestone in our effort toward preventing cervical cancers. However, screening programs will continue to serve as a critical component in prevention due to the limitations of the current vaccines. The greatest impact in cervical cancer incidence worldwide requires improved health care access to underserved areas. Advances are needed to develop single-dose, heat-stable, needle-free, and affordable formulations of the HPV vaccine to overcome the socioeconomic barriers associated with this disease.
在过去十年中，宫颈癌的研究进展阐明了人乳头瘤病毒（HPV）在宫颈癌发病机制中的作用。针对病毒样颗粒HPV疫苗的临床试验具有良好的安全性，且在预防尖锐湿疣、宫颈瘤变和宫颈癌方面疗效显著。HPV疫苗的应用是我们预防宫颈癌努力中的一个巨大里程碑。然而，由于现有疫苗存在局限性，筛查项目仍将是预防工作的关键组成部分。要在全球范围内对宫颈癌发病率产生最大影响，需要改善医疗服务可及性，尤其是在医疗服务不足的地区。还需要取得进展，开发单剂量、热稳定、无针且价格可承受的HPV疫苗制剂，以克服与该疾病相关的社会经济障碍。
